J&J completes $16.6B acquisition of Abiomed 

Johnson & Johnson Inc. closed its acquisition of Danvers medical device maker Abiomed Inc. on Thursday. The deal weighed in at $16.6 billion, making it easily one of the largest acquisitions of the year. The acquisition valued Abiomed (Nasdaq: ABMD) at $380 per share — about a 50% premium over where they were trading prior to Nov. 1, when Johnson & Johnson’s (NYSE: JNJ) proposal was first announced. Abiomed shareholders will also receive a non-tradeable contingent value right worth $35 a share in cash if Abiomed achieves certain commercial and clinical milestones.

Source: J&J completes $16.6B acquisition of Abiomed – Boston Business Journal